Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX03 vs Humira in Healthy Chinese Males
NCT03357939Phase 1Completed
- Sponsor
- Henlius
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of handayuan in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriasis (2 arms), sponsored by Henlius. Primary endpoints: Maximum Concentration and Area Under the Plasma Concentration-time Curve From Zero to Last Quantifiable Concentration. Started Jan 2017; status: completed.
02
Drugs
handayuan
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriasis
Beyond the preview
Go deeper on NCT03357939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357939.